PSNL - Personalis: Market-Leading Immuno-Oncology Platform Drives Consistent Long-Term Growth

• Personalis, Inc. is a global cancer genomics company offering genomic sequencing and data analytics solutions for comprehensive molecular data analysis for patient-specific cancers and immune responses.
• Personalis' products include: 1) ImmunoID NeXT, a universal cancer immunogenomics platform, 2) NeXT Dx Test, a comprehensive genomic testing solution, 3) Next-Gen Sequencing Research Solutions, and 4) NeXT Liquid Biopsy.
• Personalis offers various products targeting a large ~$40B market covering biopharma research, clinical and companion diagnostics, and population sequencing.
• Personalis is in a strong financial position with 2020 revenues of $78.6M and, although not profitable with a net loss of -$41M and a cash burn of -$46M, the cash position of $353M (1Q 2021) offers +7 years of cash runway.
• In summary, the author projects Personalis, Inc. as a "buy" at a 2-year price target of $35/share (+43% upside) and a 4-year price target of $69/share (+182% upside).

For further details see: